Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Earlier Diagnosis of Melanoma May Soon Become Possible Using T-Rays

By BiotechDaily International staff writers
Posted on 23 Sep 2013
Print article
Image: Layers of skin can be probed with terahertz rays in search of signs of skin cancer at its earliest stages of development (Photo courtesy of the [US] National Cancer Institute).
Image: Layers of skin can be probed with terahertz rays in search of signs of skin cancer at its earliest stages of development (Photo courtesy of the [US] National Cancer Institute).
New imaging technology has great potential to diagnose cancer at its earliest and most treatable stages.

Anis Rahman, PhD, president and chief technology officer of Applied Research & Photonics (Harrisburg, PA, USA), reported that malignant melanoma, the most lethal type of skin cancer, begins in pigment-producing cells located in the deepest part of the epidermis (the outer layer of the skin). Biochemical alterations are key characteristics of cancer occur in the melanocytes a long time before mole-like melanomas appear on the skin.

“Terahertz radiation is ideal for looking beneath the skin and detecting early signs of melanoma,” Dr. Rahman said. “T-rays are different from X-rays, which are ‘ionizing’ radiation that can cause damage. T-rays are a form of nonionizing radiation, like ordinary visible light, but they can be focused harmlessly below into the body and capture biochemical signatures of events like the start of cancer.”

T-rays occupy a position in the spectrum of electromagnetic radiation, which includes visible light and X-rays, between microwaves and infrared rays. One of the benefits of T-rays is that they penetrate only a few millimeters through skin, cloth, and other nonmetallic material.

Dr. Rahman’s research on T-rays was made through donated samples of human skin, suggesting that the technology could be valuable in diagnosing melanoma. In addition to developing T-rays for cancer diagnostics, Dr. Rahman’s team has effectively utilized them to measure the real-time absorption rates and penetration in the outer layer of skin of topically applied drugs—measurements that until now had not been possible.

Dr. Rahman presented his findings at a symposium held at the annual American Chemical Society (ACS) 2013 meeting, held September 11, 2013, in Indianapolis (IN, USA).

Related Links:
Applied Research & Photonics


Print article

Channels

Drug Discovery

view channel
Image: A scanning electron microscope (SEM) image of methicillin-resistant Staphylococcus aureus bacteria (Photo courtesy of the CDC).

Drug Combination Cures MRSA Infection While Preventing Development of Resistance

Treatment with a combination comprising the well-known antibiotic cefdinir and the experimental drug TXA709 cured mice of drug-resistant staphylococcal infections while reducing the development of resistance.... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.